<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Bay-Jensen, Anne C.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">LITHE Study Subset: Identification of Tocilizumab Early Response-Associated Biomarkers</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">15-15</style></pages><abstract><style  face="normal" font="default" size="100%">The protein fragments that are generated from metalloproteinase (MMP)-mediated protein destruction are known as neoepitopes, which serve as biomarkers of inflammation in patients with rheumatoid arthritis (RA). The aim of Randomized, Double-Blind Study of Safety and Prevention of Structural Joint Damage During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Rheumatoid Arthritis study [LITHE; NCT00106535] was to identify biomarker profiles that are associated with early response to tocilizumab in patients with RA, using neoepitope markers.</style></abstract><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>